Tesamorelin is a 44-residue synthetic analog of human growth hormone-releasing factor, hGRF(1-44)NH2, carrying one covalent modification: a trans-3-hexenoyl group added to the tyrosine at position 1 of the sequence [1]. Everything else is the natural releasing-factor backbone, amidated at the C-terminus. It is therefore best read not as a novel ligand but as the endogenous peptide with a single acyl group bolted to its N-terminus, and almost everything worth knowing about it as a research article follows from that one change.

Identity and characterization

The identity block published on the product page is the reference set to work from:

Two things fall straight out of that formula and are worth noting before any bench work. First, there is exactly one sulfur atom in the molecule. A disulfide bond requires two, so there is no intramolecular disulfide to preserve and no reducing agent needed in a buffer on that account. Second, a trans-3-hexenoyl group contributes roughly 96 Da (C6H8O) to the total mass, a small fraction of 5135.9 — by mass, the modification is close to a rounding error on a 44-residue peptide. That is the sense in which the source literature calls the analog minimally modified [1].

The chain length is also a deliberate choice worth registering. Growth hormone-releasing factor circulates and is studied in several lengths, and the shorter GHRH(1-29) fragment is the one used in the receptor work cited here — it is the fragment used in the rat renal-medulla experiments described below [7] and in the splice-variant proliferation assays [6]. Tesamorelin is built on the full 44-residue chain. Whether the additional 15 residues change anything at the receptor, as opposed to changing how the molecule behaves in a proteolytic environment, is not something the published record for this analog answers.

The molecular weight is what any molarity calculation has to run through. Ten milligrams taken into 1 mL of diluent is 10 mg/mL, which at 5135.9 g/mol is about 1.95 mM; the same mass in 5 mL is 2 mg/mL and about 0.389 mM. Reconstitution does not change the mass in the vial, only the volume it occupies.

Mechanism as studied

The receptor

Growth hormone-releasing hormone acts through the GHRH receptor, a class B G protein-coupled receptor coupled to Gs. Engagement of that receptor on pituitary somatotrophs raises intracellular cAMP, and the model built from receptor cloning and signaling work runs cAMP to protein kinase A to phosphorylation of the transcription factor CREB, with the pituitary-specific factor Pit-1 as a target gene and, in turn, a probable regulator of receptor expression [4]. The same body of work established that receptor expression in the rat is predominantly in the pituitary gland and in somatotroph cells, that glucocorticoids are positive regulators of receptor gene expression, and that a mutation in the receptor's extracellular domain which abolishes hormone binding and signaling leaves the little mouse with severely reduced somatotroph populations [5]. That work also assigns the receptor a role in somatotroph proliferation during development, not only in acute secretion [5].

The practical consequence for experimental design is that a GHRH analog is an upstream tool. It acts at the receptor for the releasing factor, one step above the growth hormone receptor itself, so any readout further down — secreted growth hormone, IGF-1, anything downstream of those — passes through a cell type that has to be present and competent in the system. In a preparation with no somatotrophs, a GHRH analog has nothing to act on unless the preparation expresses a receptor form of its own.

A 2.6 Å cryo-EM structure of the human GHRH receptor bound to its endogenous ligand and the stimulatory G protein describes how the peptide is recognized: the helical ligand forms a continuous interaction network involving the receptor's extracellular domain, all of the extracellular loops and every transmembrane helix except TM4, with the ligand's N-terminus engaging a particularly broad set of specific contacts [3].

That last detail is the one to hold onto. Tesamorelin's single modification sits on residue 1 — precisely the end of the peptide that the structural work identifies as making the most extensive receptor contacts. The structure was solved with the endogenous hormone, not with tesamorelin, so how an acyl group is accommodated at that position has not been shown directly. It is an obvious target for a structural or mutagenesis experiment and, as far as the published record goes, an open one.

What the N-terminal acyl group was reported to do

The stated rationale for the modification is proteolytic. Dipeptidyl peptidase-IV inactivates a range of bioactive peptides, growth hormone-releasing hormone among them [9]. In the non-clinical characterization of the compound, published under its development code TH9507, the trans-3-hexenoyl addition to Tyr1 was reported to make the peptide resistant to dipeptidyl aminopeptidase-IV deactivation, and the modification slowed in-vitro degradation of the peptide in rat, dog and human plasma relative to unmodified hGRF(1-44)NH2 [1].

Read that readout for what it is. It is a stability assay — how fast the peptide disappears in a proteolytically active matrix — not a receptor assay. It says the analog survives longer in plasma. It does not say the analog binds the receptor more tightly, activates it more completely, or engages it with different kinetics. The same report describes the compound as a modified GRF peptide with enhanced potency and duration of action [1], but that comparison rests on downstream biomarker responses in animals rather than on any receptor-level measurement.

It is also worth noting that the proteolytic logic does not automatically carry downstream. In growing pigs, sustained pharmacological inhibition of roughly 90% of circulating dipeptidyl peptidase-IV activity did not raise circulating IGF-1 — the trend ran in the opposite direction — while GHRH itself did raise it in the same study [9]. Protecting a peptide from one protease and moving an endpoint are separate questions, and in that experiment they came apart.

What model systems it has actually been examined in

The published record for tesamorelin specifically is narrow, and it is worth being precise about what exists.

  • Plasma degradation in vitro: rat, dog and human plasma, comparing the analog with unmodified hGRF(1-44)NH2 [1]. This is the closest thing to a mechanistic bench assay in the compound's own literature.
  • Whole-animal biomarker studies: pigs, rats and dogs, with plasma growth hormone and IGF-1 as the measured outputs [1].
  • Repeat-administration toxicology: up to four months in rats and dogs. A significant but not dose-related increase in body weight gain was reported alongside the biomarker response; in dogs, reversible liver and kidney findings, hematological and clinical chemistry changes and organ weight effects were attributed by the authors to prolonged exposure to supraphysiological levels of growth hormone and/or IGF-1 [1].
  • Disposition in the dog: terminal half-lives on the order of 26 to 39 minutes, quantified by radioimmunoassay [2], with the broader characterization reporting apparent elimination half-lives in dogs of 21 to 45 minutes [1].

The radioimmunoassay point matters, and the authors flag it themselves, reporting immunoreactive TH9507 [1] and measuring plasma levels by radioimmunoassay [2]. An immunoassay reports antibody-recognizable material, which can include fragments that still carry the epitope. Half-life figures derived that way are not the same as half-lives for intact, receptor-competent peptide, and a mass-spectrometric comparison does not appear in the published record.

For anything at the level of cultured cells, the relevant literature is about GHRH and its receptor rather than about this analog. Receptor splice variants have been detected outside the pituitary; when the SV1 variant was expressed in 3T3 mouse fibroblasts, radioligand binding detected high-affinity GHRH binding sites with a Kd near 0.58 nM and a maximal binding capacity near 103 fmol/mg of membrane protein, absent in empty-vector controls, and GHRH analogs then raised cAMP and cell proliferation in the transfected cells with no growth hormone release; vasoactive intestinal peptide had no effect in that system [6]. A functional receptor has also been localized in the rat renal medulla, restricted to Henle's loop, where a four-hour incubation with rat GHRH(1-29)NH2 lowered receptor mRNA levels in cultured cells and a fluorescently labeled GHRH analog was internalized in a time- and temperature-dependent manner [7]. Those are useful model systems for the receptor. None of them was run with tesamorelin.

What the evidence does not establish

Several gaps are large enough that a researcher should plan around them rather than assume the numbers exist somewhere.

  • No published receptor-level pharmacology for tesamorelin. Searching the compound name and its development code does not surface a binding constant or a functional EC50 at the cloned human GHRH receptor. The potency language in the literature is inferred from downstream biomarkers in animals, not measured at the receptor [1].
  • No structure of the analog bound to the receptor. The available structural work used the endogenous hormone [3], so the fate of an acyl group at the position making the most extensive receptor contacts is unresolved.
  • No selectivity profile. The GHRH receptor sits in a family with close relatives that share ligand architecture. Cross-reactivity of this specific analog against those receptors is not reported.
  • No data on extrapituitary receptor forms. Splice variants that bind GHRH analogs and signal through cAMP exist in non-pituitary cells [6], and a functional receptor exists in rat kidney [7], but whether tesamorelin engages either has not been tested in print.
  • No cell-culture characterization of the compound itself. No published concentration-response curve for tesamorelin in any cultured cell system could be located.

The shape of this literature is unusual and worth stating plainly. The record moved to whole-animal and downstream endpoints early, and the bench characterization that normally accumulates underneath a tool compound largely did not get done. Anyone reaching for tesamorelin as a defined GHRH-receptor agonist is reaching for a molecule whose in-vitro parameters have not been published, and should expect to generate them rather than cite them.

Handling and stability

The material is supplied as a lyophilized powder and stored refrigerated at 2–8 °C. Beyond that, the literature supports one specific and genuinely useful point about GRF-family peptides in solution.

Degradation of growth hormone-releasing factor analogs in neutral aqueous solution runs mainly through deamidation of asparagine residues [8]. For [Leu27]hGRF(1-32)NH2 incubated at pH 7.4 and 37 °C, the major products were the beta-Asp8 and alpha-Asp8 peptides. Tested as growth hormone secretagogues in cultured bovine anterior pituitary cells, the beta-Asp8 form was estimated at 400- to 500-fold less potent than the parent peptide and the alpha-Asp8 form about 25-fold less potent. Replacing Asn8 with serine extended the disappearance half-life at pH 7.4 and 37 °C from 202 hours for the parent to roughly 1550 hours [8].

Two cautions on transferring that. It was measured on a shorter GRF analog carrying a leucine substitution, not on tesamorelin, so the half-life figures are indicative rather than a specification for this molecule. But the underlying chemistry is a property of asparagine in a peptide backbone, and tesamorelin retains the natural GRF sequence including its asparagines — the hexenoyl group at Tyr1 addresses proteolysis, not deamidation. The practical reading is that a reconstituted stock held at neutral pH and warm temperature can lose activity by a route that a purity assay may resolve poorly, since a deamidated peptide differs from its parent by only about 1 Da.

Oxidation of the single sulfur-containing residue is a plausible additional route by analogy with other sulfur-containing peptides, but no published stability study of tesamorelin reports it. That makes it a hypothesis to check, not a known behavior.

Open questions

The list of what a well-designed experiment could contribute here is short and unusually concrete. What are the binding affinity and functional potency of tesamorelin at the cloned human GHRH receptor, measured side by side with hGRF(1-44)NH2? Does the trans-3-hexenoyl group at Tyr1 cost anything at the receptor, given that the N-terminus makes the most extensive contacts in the solved structure [3]? Does the analog engage the extrapituitary receptor splice variants that respond to other GHRH analogs [6]? Does its half-life measured by mass spectrometry match the half-life measured by radioimmunoassay [1, 2]? And what is the solution-phase degradation profile of this specific sequence at defined pH and temperature, given how sharply deamidation cost potency in the related analog [8]?

Until those are answered, tesamorelin is best regarded as a well-identified compound with a thin mechanistic file. The chemistry is clear, the receptor biology of its parent hormone is described in detail, and the bridge between the two has largely not been built.